Centiva Capital, LP
Institutional investor · Portfolio as of Q2 2026
Top Holdings1,787 positions
Nvidia Corp | 3.8M | $756.4M | 6.6% | — | — | — | Decreased — |
iShares Russell 2000 ETF | 1.8M | $533.8M | 4.7% | — | — | — | Decreased — |
Invesco QQQ Trust Series 1 | 540,700 | $398.2M | 3.5% | — | — | — | Decreased — |
Nvidia Corp | 2M | $391.9M | 3.4% | $186.42 | +18.71% | 18 qtrssince 2022-Q1 | Increased 80 |
Invesco QQQ Trust Series 1 | 368,600 | $271.4M | 2.4% | — | — | — | Decreased — |
Meta Platforms Inc | 448,700 | $252.7M | 2.2% | — | — | — | Decreased — |
ISHARES CORE S&P 500 ETF | 319,957 | $240.2M | 2.1% | $746.73 | +3.53% | 1 qtr | New 79 |
SPDR S&P Regional Banking | 2.9M | $219.3M | 1.9% | — | — | — | Increased — |
Alphabet Inc | 590,600 | $211.1M | 1.8% | — | — | — | Increased — |
Microsoft Corp. | 563,600 | $210.2M | 1.8% | — | — | — | Increased — |
Apple Inc | 718,600 | $207.9M | 1.8% | — | — | — | Decreased — |
Alphabet Inc CL C | 526,300 | $186M | 1.6% | — | — | — | Decreased — |
Meta Platforms Inc | 295,600 | $166.5M | 1.5% | — | — | — | Decreased — |
UnitedHealth Group Inc | 362,100 | $150.5M | 1.3% | — | — | — | Increased — |
Marvell Technology Inc | 481,800 | $143.5M | 1.3% | — | — | — | Decreased — |
Amazon.com Inc | 547,600 | $130.5M | 1.1% | — | — | — | Decreased — |
VANECK ETF TRUST | 189,400 | $124.2M | 1.1% | — | — | — | New — |
iShares iBoxx USD High Yield Corporate Bond ETF | 1.4M | $112M | 1.0% | — | — | — | Decreased — |
Goldman Sachs Group Inc/The | 102,000 | $103.2M | 0.9% | — | — | — | Increased — |
Tesla Inc | 242,400 | $102M | 0.9% | — | — | — | Decreased — |
Centiva Capital, LP manages $11.5B across 1787 positions as of Q2 2026. Top holdings: NVDA puts (6.6%), IWM puts (4.7%), QQQ puts (3.5%). Fund DNA: Momentum Trader. HoldingsIntel Score: 1/5.0.
Active quarter - 625 new positions, 471 exits, 294 increased. Top move: NVDA (INCREASED, conviction 80). Portfolio: $11.5B across 1787 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR